KR101242941B1 - Composition for Atopy Skin Using an Extract of Bamboo Leaves and an Extract of Root of Polygonum - Google Patents
Composition for Atopy Skin Using an Extract of Bamboo Leaves and an Extract of Root of Polygonum Download PDFInfo
- Publication number
- KR101242941B1 KR101242941B1 KR1020100091880A KR20100091880A KR101242941B1 KR 101242941 B1 KR101242941 B1 KR 101242941B1 KR 1020100091880 A KR1020100091880 A KR 1020100091880A KR 20100091880 A KR20100091880 A KR 20100091880A KR 101242941 B1 KR101242941 B1 KR 101242941B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- atopic dermatitis
- present
- root
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 239000000284 extract Substances 0.000 title claims abstract description 73
- 235000017166 Bambusa arundinacea Nutrition 0.000 title description 8
- 235000017491 Bambusa tulda Nutrition 0.000 title description 8
- 235000015334 Phyllostachys viridis Nutrition 0.000 title description 8
- 239000011425 bamboo Substances 0.000 title description 8
- 206010003645 Atopy Diseases 0.000 title description 5
- 241001330002 Bambuseae Species 0.000 title 1
- 241000205407 Polygonum Species 0.000 title 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 42
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000002537 cosmetic Substances 0.000 claims description 12
- 239000000344 soap Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 6
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 210000003630 histaminocyte Anatomy 0.000 abstract description 5
- 241000218671 Ephedra Species 0.000 abstract description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 239000006210 lotion Substances 0.000 description 12
- 239000000796 flavoring agent Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical class OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 8
- -1 multiphase) Substances 0.000 description 8
- 244000082204 Phyllostachys viridis Species 0.000 description 7
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 7
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000003995 emulsifying agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 239000004909 Moisturizer Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 229960000541 cetyl alcohol Drugs 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001333 moisturizer Effects 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 240000008866 Ziziphus nummularia Species 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- OMRLTNCLYHKQCK-DHGKCCLASA-N 4-nitrophenyl N-acetyl-beta-D-glucosaminide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([N+]([O-])=O)C=C1 OMRLTNCLYHKQCK-DHGKCCLASA-N 0.000 description 2
- 244000144927 Aloe barbadensis Species 0.000 description 2
- 235000002961 Aloe barbadensis Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 244000292697 Polygonum aviculare Species 0.000 description 2
- 235000006386 Polygonum aviculare Nutrition 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940086555 cyclomethicone Drugs 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 108010067755 dinitrophenyl-bovine serum albumin Proteins 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 235000021096 natural sweeteners Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical class CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical class O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 102100021936 C-C motif chemokine 27 Human genes 0.000 description 1
- 101710112538 C-C motif chemokine 27 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102100031107 Disintegrin and metalloproteinase domain-containing protein 11 Human genes 0.000 description 1
- 101710121366 Disintegrin and metalloproteinase domain-containing protein 11 Proteins 0.000 description 1
- 238000010159 Duncan test Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 239000004386 Erythritol Chemical class 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Chemical class OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Chemical class 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 241000064501 Prunus sachalinensis Species 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 244000042430 Rhodiola rosea Species 0.000 description 1
- 235000003713 Rhodiola rosea Nutrition 0.000 description 1
- 241000208422 Rhododendron Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- PSUBPFRWJHQJIA-UHFFFAOYSA-K [Ca+2].C(C=CC=CC)(=O)[O-].[Na+].C(C=CC=CC)(=O)[O-].C(C=CC=CC)(=O)[O-] Chemical compound [Ca+2].C(C=CC=CC)(=O)[O-].[Na+].C(C=CC=CC)(=O)[O-].C(C=CC=CC)(=O)[O-] PSUBPFRWJHQJIA-UHFFFAOYSA-K 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 229940095602 acidifiers Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000004301 calcium benzoate Substances 0.000 description 1
- 235000010237 calcium benzoate Nutrition 0.000 description 1
- HZQXCUSDXIKLGS-UHFFFAOYSA-L calcium;dibenzoate;trihydrate Chemical compound O.O.O.[Ca+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 HZQXCUSDXIKLGS-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 210000003426 epidermal langerhans cell Anatomy 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical class OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical class CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001223 polyethylene glycol Chemical class 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000004300 potassium benzoate Substances 0.000 description 1
- 235000010235 potassium benzoate Nutrition 0.000 description 1
- 229940103091 potassium benzoate Drugs 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D9/00—Compositions of detergents based essentially on soap
- C11D9/04—Compositions of detergents based essentially on soap containing compounding ingredients other than soaps
- C11D9/22—Organic compounds, e.g. vitamins
- C11D9/38—Products in which the composition is not well defined
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 대잎 추출물과 호장근 추출물을 이용한 아토피 피부염 개선제 조성물을 개시한다. 대잎 추출물과 호장근 추출물은 뛰어난 비만세포의 탈과립 억제 활성을 가지며 높은 아토피 피부염 개선 활성을 보인다. The present invention discloses an atopic dermatitis improving agent composition using a leaf extract and ephedra root extract. Leaf extract and K. koji extract have excellent degranulation inhibitory activity of mast cells and high atopic dermatitis improving activity.
Description
본 발명은 대잎 추출물과 호장근 추출물을 이용한 아토피 피부염 개선제 조성물에 관한 것이다.
The present invention relates to an atopic dermatitis improving agent composition using the extract of the leaves and ephedra root.
아토피는 라틴어 'atopia'에서 유래한 말로서 '괴상한' 또는 "부적절한"의 의미를 가지고 있다.Atopy is a word derived from the Latin word "atopia", meaning "weird" or "inappropriate."
아토피 피부염의 원인은 아직까지 명확히 규명되어 있지 않지만, IgE 생성의 증가, CD8+ 억제/세포독성 T 림프구 (CD8+ suppressor/cytotoxic T lymphocytes) 수적 감소와 기능 저하, IFN-γ를 분비하는 Th1(T-cell Helper type 1) 림프구의 수적 감소, 단핵구/대식세포의 침윤, 비만세포, 호산구, 수지상세포(dendritic cells; DCs), 표피의 랑게르한스 세포 및 CD4+ T 림프구의 수적 증가, Th1 세포에 비해 Th2 세포의 수적 증가, 사이토카인(IL-10, IL-4, IL-5, TNF-α 등)의 생성 증가, 케모카인(TSLP, RANTES, CTACK, LARC, MDC, TARC 등)의 생성 증가 등의 면역학적 현상들이 보고되고 있고[J. Invest. Dermatol., 96:523-526, 1991; J. Invest Dermatol., 97:389-394, 1991; Immunol., 11:81-88, 1999; Curr Drug Targets Inflamm Allergy., 2:199-120, 2003; J. Allergy Clin Immunol., 107:871-877, 2001; Adv. Immunol. 78:57, 2001; International Immunology, 14(7):767-773, 2002; Pediatr Allergy Immunol 19: 605-613, 2008], 통상 아토피 피부염을 앓고 있는 사람이 집 먼지, 진드기, 동물의 털, 음식물, 꽃가루, 곰팡이 등과 같이 외부환경의 이물질에 대해 알러지 반응을 나타내는 점과 또 아토피 피부염이 알러지성 비염, 천식, 결막염, 장관염 등을 동반한다는 점에서 면역 체계의 교란에 의하여 발생하는 것으로 추정되고 있다.The cause of atopic dermatitis has not yet been elucidated, but increased IgE production, decreased number and decreased function of CD8 + suppressor / cytotoxic T lymphocytes, and Th1 (T-cell) secreting IFN-γ. Helper type 1) Decreased lymphocyte counts, monocyte / macrophage infiltration, mast cells, eosinophils, dendritic cells (DCs), epidermal Langerhans cells and CD4 + T lymphocytes, and Th2 cells compared to Th1 cells Immunological phenomena such as increased production of cytokines (IL-10, IL-4, IL-5, TNF-α, etc.) and increased production of chemokines (TSLP, RANTES, CTACK, LARC, MDC, TARC, etc.) Is being reported [J. Invest. Dermatol., 96: 523-526, 1991; J. Invest Dermatol., 97: 389-394, 1991; Immunol., 11: 81-88, 1999; Curr Drug Targets Inflamm Allergy., 2: 199-120, 2003; J. Allergy Clin Immunol., 107: 871-877, 2001; Adv. Immunol. 78:57, 2001; International Immunology, 14 (7): 767-773, 2002; Pediatr Allergy Immunol 19: 605-613, 2008], People with atopic dermatitis usually have allergic reactions to foreign objects such as house dust, mites, animal hair, food, pollen, and fungi, as well as atopy It is estimated that dermatitis is caused by disturbance of immune system in that it is accompanied by allergic rhinitis, asthma, conjunctivitis, enteritis.
현재 사용하고 있는 치료약 중 스테로이드계 약품(부신피질호르몬제)은 소염 작용 및 면역 억제 작용이 우수하지만, 장기간 사용할 경우 피부에 털이 나고 피부가 위축될 수 있으며, 피부 색소가 적어지고 세균의 감염이 생기며, 여드름이 돋고, 피부가 얇아지고 실핏줄이 드러나는 등의 부작용을 갖고 있다.Among the currently used therapeutic drugs, steroid drugs (adrenal corticosteroids) have excellent anti-inflammatory and immunosuppressive effects, but when used for a long time, they can cause hair to become thin and shrink, skin pigments and bacterial infections. It has side effects such as acne, skin thinning, and blood vessels.
최근 기존 화학 약품의 부작용을 최소화하기 위하여, 아토피 피부염에 효과가 있는 천연물을 찾고자 하는 노력이 활발해지고 있다. 아토피 피부염 개선 활성이 있다고 보고된 천연물로서는 지부자, 용규, 명아주 등의 혼합추출물(국내 특허 제0589667호), 애기수영 추출물 또는 대황 추출물(국내 특허 제066829호), 뱀딸기 추출물(국내 특허 제066642호) 등을 들 수 있다. Recently, in order to minimize side effects of existing chemicals, efforts to find natural products effective for atopic dermatitis have been actively made. Natural products that have been reported to improve atopic dermatitis include branched extracts, yonggyu, and mingled liquor mixed extracts (domestic patent no. Etc. can be mentioned.
본 발명도 천연 추출물의 아토피 피부염의 개선 효과를 개시한다.
The present invention also discloses an improvement effect of atopic dermatitis of natural extracts.
본 발명의 목적은 천연물로서 대잎 추출물과 호장근 추출물을 이용한 아토피 피부염 개선제 조성물을 제공하는 데 있다.It is an object of the present invention to provide an atopic dermatitis improving agent composition using the extract of the leaves and ephedra root as a natural product.
본 발명의 구체적인 목적은 이하에서 제시될 것이다.
The specific object of the present invention will be presented below.
본 발명자는 아래의 참조예, 실시예 및 실험예에서 확인되는 바와 같이, 대잎의 70% 에탄올 추출물과 호장근의 70% 에탄올 추출물 그리고 이들 추출물의 동량이 혼합물을 IgE 및 항원(DNP-BSA)으로 활성화시킨 비만세포주 RBL-2H3(rat basophilic leukemia)에 처리한 결과, 대잎 추출물 또는 호장근 추출물을 단독으로 처리하였을 때에 비하여 베타-헥소사미니다아제(β-hexosaminidase)의 생성이 현저히 억제됨을 확인할 수 있었다. The inventors have identified 70% ethanol extract of jujube and 70% ethanol extract of Escherichia coli and the same amount of these extracts as IgE and antigen (DNP-BSA), as confirmed in the following Reference Examples, Examples and Experimental Examples. As a result of treatment with activated mast cell line RBL-2H3 (rat basophilic leukemia), it was confirmed that beta-hexosaminidase production was significantly suppressed compared with the treatment with the extract of the leaf or the ephedra root alone. .
아토피 피부염에 있어서 비만세포의 수가 증가하고 탈과립 상태를 나타내며, 탈과립에 의하여 방출된 히스타민이 단독 또는 다른 인자와 함께 아토피 피부염에 작용하는 것으로 알려져 있는데[J Invest Dermatol. 102:28-37 (1994); Mini Rev Med Chem. 4(9):923-33 (2004); J Dermatol Sci. 33(1):23-9 (2003); J Drugs Dermatol. 3(6):632-9 (2004)], 비만세포주인 RBL-2H3는 그 표면에 IgE 항체의 수용체(FcεRI)를 갖고 있어 IgE와 항원으로 활성화되면 탈과립이 유도되어 히스타민 등의 알러지 반응의 매개물질을 분비하는 것으로 알려져 있는 세포이며, 베타-헥소사미니다아제는 탈과립의 지표 물질로 알려져 있다[Planta Med. 64:577-578 (1998)]. In atopic dermatitis, the number of mast cells is increased and degranulation is shown, and histamine released by degranulation is known to act on atopic dermatitis alone or in combination with other factors [J Invest Dermatol. 102: 28-37 (1994); Mini Rev Med Chem. 4 (9): 923-33 (2004); J Dermatol Sci. 33 (1): 23-9 (2003); J Drugs Dermatol. 3 (6): 632-9 (2004)], the mast cell line RBL-2H3 has an IgE antibody receptor (FcεRI) on its surface. When activated with IgE and antigen, degranulation is induced to mediate allergic reactions such as histamine. Cells are known to secrete substances, and beta-hexosaminidase is known as an indicator of degranulation [Planta Med. 64: 577-578 (1998).
본 발명자는 상기 실험 결과에 기초하여 대잎 추출물, 호장근 추출물 또는 이들 추출물의 혼합물을 포함하여 화장수 조성물을 제조하고 SCORAD 지수로 아토피 피부염 개선 활성을 임상평가하였는데, 상기 세포 실험과 유사한 경향을 보이며 대잎 추출물과 호장근 추출물의 혼합물이 포함된 화장수 조성물이 가장 높은 아토피 피부염 개선 활성을 나타내었다.The inventors of the present invention prepared a cosmetic composition comprising a leaf extract, Keun-Geun extract or a mixture of these extracts and clinically evaluated the atopic dermatitis improving activity using the SCORAD index. The lotion composition containing a mixture of the extract and the E. coli showed the highest atopic dermatitis improving activity.
본 발명은 이러한 실험 결과에 기초하여 제공되는 것으로서, 본 발명의 아토피 피부염 개선제 조성물은 대잎 추출물 및 호장근 추출물을 유효성분으로 포함함을 특징으로 한다.The present invention is provided based on the results of the experiment, the atopic dermatitis improving composition of the present invention is characterized in that it comprises the extract of the leaf and E.
본 명세서에서, "대잎 추출물"이란 추출 방법을 불문하고 추출 대상인 대잎(bamboo leaf)을 메탄올, 에탄올, 아세톤, 에틸아세테이트, 포화노말부탄올, 클로로포름, 메틸렌클로라이드, 물 또는 이들의 혼합 용매로 추출하여 얻어진 추출물과 그 추출물에서 상기 열거된 용매로 분획된 추출물을 포함하는 의미로서 이해된다. 추출 방법을 불문하므로, 추출 대상인 대잎을 추출 용매에 침지시키는 단계를 통하여 추출되는 한, 추출 방법은 냉침, 환류, 가온, 초음파 등 임의의 방식이 모두 적용될 수 있는 것으로 이해되어야 한다. 그럼에도 상기 "대잎 추출물"은 바람직하게는 추출 대상인 대잎을 물, 에탄올 또는 이들의 혼합 용매로 추출하고 얻어진 것으로서, 추출 용매가 제거된 농축된 액상의 추출물 또는 고형상의 추출물을 포함하는 의미이다.In the present specification, the term “bamboo leaf extract” is obtained by extracting a bamboo leaf, which is an extraction method, with methanol, ethanol, acetone, ethyl acetate, saturated normal butanol, chloroform, methylene chloride, water or a mixed solvent thereof regardless of the extraction method. It is understood as meaning including the extract and the extract fractionated with the solvents listed above in the extract. Regardless of the extraction method, it should be understood that the extraction method can be applied to any method such as cold soaking, refluxing, heating, and ultrasonic wave, as long as the extraction target is extracted by immersing the target leaf in the extraction solvent. Nevertheless, the "leaf extract" is preferably obtained by extracting the leaf to be extracted with water, ethanol or a mixed solvent thereof, and is meant to include a concentrated liquid extract or solid extract from which the extraction solvent is removed.
또한 본 명세서에서, "호장근 추출물"은 추출 대상이 호장근인 점을 제외하고는 상기 "대잎 추출물"과 동일하게 정의될 수 있다. 여기서 "호장근"이란 마디풀과(Polygonaceae)에 속하는 다년생 본초인 호장과 호장속 근연식물의 근경(根莖)과 근(根)을 건조시켜 얻은 것을 말한다. 통상은 수근(鬚根)을 제거하여 얻는다. 우리나라에는 호장근은 호장(Polygonum cuspidatum Sieb. et Zucc.), 왕호장(P. sachalinensis Fr. Schm.) 및 둥근잎호장(P. elliticum Migo)의 3종이 있다고 알려져 있다(이창복: 서울大學校 論文集 生農系 第20輯 p89, 1969). In addition, in the present specification, "knotweed extract" may be defined in the same manner as the "leaf extract" except that the extraction target is knotweed. Here, "hojanggeun" refers to the roots and roots of perennial herbaceous roots of the genus Polygonaceae. Usually obtained by removing carpal roots. In Korea, Ho Jang Geun is called Polygonum cuspidatum Sieb. et Zucc.), P. sachalinensis Fr. Schm. and P. elliticum Migo are known to have three species (Lee Chang-bok: 20, p89, 1969). .
본 명세서에서, "아토피 피부염"은 모든 유형의 아토피 피부염을 포함하는 의미이다. 통상 아토피 피부염은 그 발병 시기 또는 그 발명 대상에 따라 유아형 아토피 피부염과 소아형 아토피 피부염과 성인형 아토피 피부염 그리고 임산부 아토피 피부염으로 분류되는데, 상기 아토피 피부염이 의미에는 이러한 모든 유형의 아토피 피부염이 포함된다. As used herein, "atopic dermatitis" is meant to include all types of atopic dermatitis. Atopic dermatitis is generally classified into juvenile atopic dermatitis, juvenile atopic dermatitis, adult atopic dermatitis, and maternal atopic dermatitis according to the time of its onset or the subject of the invention, which includes all these types of atopic dermatitis. .
또 본 명세서에서, "개선"이란 증상의 경감, 예방 및/또는 치료를 포함하는 의미이다. In addition, in this specification, "improvement" is meant to include alleviation, prevention and / or treatment of symptoms.
또 본 명세서에서, "유효성분"이란 단독으로 활성을 나타내거나 또는 그 자체는 활성이 없는 보조제(담체)와 함께 활성을 나타내는 성분을 말한다.In addition, in this specification, an "active ingredient" means the component which shows activity alone or shows itself activity with the adjuvant (carrier) which is inactive.
본 명세서에서 특별히 정의되지 아니한 기타의 용어는 국어사전적 의미나 당업계에서 일반적으로 받아들여지고 있는 의미를 따른다.Other terms not specifically defined in this specification are intended to refer to either a national language meaning or a commonly accepted meaning in the art.
한편 본 발명의 아토피 개선제 조성물은 그 유효성분인 대잎 추출물과 호장근 추출물을 아토피 피부염 개선 활성을 나타낼 수 있는 한 용도, 제형, 배합 목적 등에 따라 임의의 양(유효량)으로 포함할 수 있는데, 통상적인 유효량은 조성물 전체 중량을 기준으로 할 때 0.001 중량 % 내지 99.900 중량 % 범위 내에서 결정될 것이다. 여기서 "유효량"이란 아토피 피부염의 예방, 개선, 치료, 또는 그 증상의 발현 지연을 유도할 수 있는 유효성분의 양을 말한다. 이러한 유효량은 당업자의 통상의 능력 범위 내에서 실험적으로 결정될 수 있다.On the other hand, the atopy improving composition of the present invention may include any amount (effective amount) according to the purpose, formulation, formulation purposes, etc., as long as it can exhibit the atopic dermatitis improving activity of the extracts of the active leaf and the extract of e. An effective amount will be determined within the range of 0.001% to 99.900% by weight based on the total weight of the composition. As used herein, the term "effective amount" refers to an amount of an active ingredient that can induce the prevention, improvement, treatment of atopic dermatitis, or delay the onset of its symptoms. Such effective amounts can be determined experimentally within the ordinary skill of those skilled in the art.
본 발명의 아토피 개선제 조성물은 구체적인 양태에 있어서 화장품 조성물로 파악할 수 있다.The atopy improving agent composition of this invention can be grasped | ascertained as a cosmetic composition in a specific aspect.
본 발명의 조성물이 화장품 조성물로서 파악될 경우, 그 화장품 조성물은 다양한 형태로 제조될 수 있는데, 예컨대, 에멀젼, 로션, 크림(수중유적형, 유중수적형, 다중상), 용액, 현탁액(무수 및 수계), 무수 생성물(오일 및 글리콜계), 젤, 마스크, 팩 또는 분말 등의 제형으로 제조될 수 있다.When the composition of the present invention is conceived as a cosmetic composition, the cosmetic composition can be prepared in various forms, for example, emulsions, lotions, creams (oil-in-water, water-in-oil, multiphase), solutions, suspensions (anhydrous and Aqueous), anhydrous products (oil and glycol based), gels, masks, packs or powders.
본 발명의 조성물은 그 유효성분 이외에 화장품 제제에 있어서 수용가능한 담체를 포함할 수 있다. The composition of the present invention may contain an acceptable carrier in cosmetic preparations in addition to its active ingredients.
여기서 "화장품 제제에 있어서 수용가능한 담체"란 화장품 제제에 포함될 수 있는 이미 공지되어 사용되고 있는 화합물 또는 조성물이거나 앞으로 개발될 화합물 또는 조성물로서 피부와의 접촉시 인체가 적응 가능한 독성 이상의 독성이 없는 것을 말한다.As used herein, the term " acceptable carrier for a cosmetic preparation "refers to a compound or composition which is already known and used in the cosmetic preparation, or which is a compound or composition to be developed in the future, and which is not toxic to the human body.
상기 담체는 본 발명의 조성물에 그것의 전체 중량에 대하여 약 1 중량 % 내지 약 99.99 중량 %, 바람직하게는 조성물의 중량의 약 50 중량% 내지 약 99 중량 %로 포함될 수 있다. The carrier may be included in the composition of the present invention in an amount of from about 1% by weight to about 99.99% by weight, preferably from about 50% by weight to about 99% by weight of the composition, based on the total weight thereof.
그러나 상기 비율은 화장품의 전술한 바의 제형에 따라 또 그것의 구체적인 적용 부위(얼굴이나 손)나 그것의 바람직한 적용량 등에 따라 달라지는 것이기 때문에, 상기 비율은 어떠한 측면으로든 본 발명의 범위를 제한하는 것으로 이해되어서는 안 된다. However, since the ratio depends on the above-mentioned formulation of the cosmetic product and its specific application site (face or hands) or the desired amount of application thereof, the ratio is to limit the scope of the present invention in any aspect It should not be.
한편, 상기 담체로서는 알코올, 오일, 계면활성제, 지방산, 실리콘 오일, 습윤제, 보습제, 점성 변형제, 유제, 안정제, 자외선 차단제, 발색제, 향료 등이 예시될 수 있다. Examples of the carrier include alcohols, oils, surfactants, fatty acids, silicone oils, humectants, moisturizers, viscosifiers, emulsifiers, stabilizers, sunscreens, coloring agents and perfumes.
상기 담체로서 사용될 수 있는 알코올, 오일, 계면활성제, 지방산, 실리콘 오일, 습윤제, 보습제, 점성 변형제, 유제, 안정제, 자외선 차단제, 발색제, 향료 로 사용될 수 있는 화합물/조성물 등은 이미 당업계에 공지되어 있기 때문에 당업자라면 적절한 해당 물질/조성물을 선택하여 사용할 수 있다.The compounds / compositions which can be used as the carrier and which can be used as alcohols, oils, surfactants, fatty acids, silicone oils, wetting agents, moisturizers, viscosifiers, emulsions, stabilizers, sunscreens, A person skilled in the art can select and use appropriate substances / compositions.
본 발명의 조성물은 또 다른 구체적인 양태에 있어 비누 조성물로서 파악될 수 있다.The composition of the present invention can be identified as a soap composition in another specific embodiment.
본 발명의 조성물이 비누 조성물로서 파악될 경우에, 본 발명의 비누 조성물은 비누 기재에 유효성분을 포함하여 제조될 수 있으며, 첨가제로서 피부 보습제, 유화제, 경수 연화제 등을 포함하여 제조될 수 있다.When the composition of the present invention is identified as a soap composition, the soap composition of the present invention can be prepared by incorporating an active ingredient into a soap base, and can be prepared as an additive including a skin moisturizer, an emulsifier, a water softener and the like.
상기 비누 기재로서는 야자유, 팜유, 대두유, 파마자유, 올리브유, 팜핵류 등의 식물유지 또는 우지, 돈지, 양지, 어유 등의 동물유지 등이 사용될 수 있고, 상기 피부 보습제로서는 글리세린, 에리트리톨, 폴리에틸렌글리콜, 프로필렌글리콜, 부틸렌글리콜, 펜틸렌글리콜, 헥실글리콜, 이소프로필미리스테이트, 실리콘 유도체, 알로에베라, 솔비톨 등이 사용될 수 있으며, 상기 유화제로서는 천연오일, 왁스 지방알콜, 탄화수소류, 천연식물 추출물 등이 사용될 수 있고, 상기 경수연화제로서는 테트라소듐 이디티에이 등이 사용될 수 있다.Examples of the soap base material include vegetable oils such as palm oil, palm oil, soybean oil, perm free oil, olive oil and palm kernel oil or animal fats such as tallow, lard, sunshine and fish oil. Examples of the skin moisturizers include glycerin, erythritol, polyethylene glycol , Propylene glycol, butylene glycol, pentylene glycol, hexyl glycol, isopropyl myristate, silicone derivatives, aloe vera, sorbitol and the like. Examples of the emulsifier include natural oils, wax fatty alcohols, hydrocarbons, May be used. As the water softening agent, tetrasodium ethylenediate and the like may be used.
본 발명의 비누 조성물은 또한 첨가제로서 항균제, 분산제, 거품억제제, 용매, 물때 방지제, 부식 방지제, 향료, 색소, 금속이온 봉쇄제, 산화방지제, 방부제 등을 추가적으로 포함할 수 있다.The soap composition of the present invention may further contain, as an additive, an antibacterial agent, a dispersant, a foam inhibitor, a solvent, a scouring inhibitor, a corrosion inhibitor, a fragrance, a dye, a sequestering agent, an antioxidant and an antiseptic.
본 발명의 비누 조성물에 있어서, 비누 기재나 첨가제는 당업계에 일반적으로 사용되고 있는 함량으로 포함될 수 있는데, 비누 기재는 일반적으로 비누 조성물의 전체 중량을 기준으로 하였을 때 99.999 중량 % 내지 50 중량 %로 첨가될 수 있으며, 첨가제는 1 중량 % 내지 20 중량 %로 첨가될 수 있다. In the soap composition of the present invention, the soap base or additive may be included in a content commonly used in the art, wherein the soap base generally comprises from 99.999% to 50% by weight, based on the total weight of the soap composition And the additive may be added in an amount of 1 wt% to 20 wt%.
본 발명의 조성물은 다른 구체적인 양태에 있어서 약제학적 조성물로 파악될 수 있다.The composition of the present invention may be regarded as a pharmaceutical composition in another specific embodiment.
본 발명의 약제학적 조성물은 그 유효성분 이외에 약제학적으로 허용되는 담체, 부형제 등을 포함하여, 경구용 제형(정제, 현탁액, 과립, 에멀젼, 캡슐, 시럽 등), 비경구형 제형(멸균 주사용 수성 또는 유성 현탁액), 국소형 제형(크림, 로션, 연고(반고형의 외용약), 마이크로로에멀젼, 젤, 페이스트, 경피제제(TTS)(예컨대 패치제, 붕대 등) 등으로 제조될 수 있다.Pharmaceutical compositions of the present invention, in addition to its active ingredients, include pharmaceutically acceptable carriers, excipients, and the like, oral formulations (tablets, suspensions, granules, emulsions, capsules, syrups, etc.), parenteral formulations (sterile injectable aqueous solutions). Or oily suspensions), topical formulations (creams, lotions, ointments (semi-solid external preparations), microroemulsions, gels, pastes, transdermal agents (TTS) (such as patches, bandages, etc.), and the like.
상기에서 "약제학적으로 허용되는" 의미는 유효성분의 활성을 억제하지 않으면서 적용(처방) 대상이 적응가능한 이상의 독성을 지니지 않는다는 의미이다.The term "pharmaceutically acceptable" as used herein means that the application (prescribing) subject does not have the above-mentioned toxicity that is adaptable without inhibiting the activity of the active ingredient.
약제학적으로 허용되는 담체의 예로서는 락토스, 글루코스, 슈크로스, 전분(예컨대 옥수수 전분, 감자 전분 등), 셀룰로오스, 그것의 유도체(예컨대 나트륨 카르복시메틸 셀룰로오스, 에틸셀룰로오스, 등), 맥아, 젤라틴, 탈크, 고체 윤활제(예컨대 스테아르산, 스테아르산 마그네슘 등), 황산 칼슘, 식물성 기름(예컨대 땅콩 기름, 면실유, 참기름, 올리브유 등), 폴리올(예컨대 프로필렌 글리콜, 글리세린 등), 알긴산, 유화제(예컨대 TWEENS), 습윤제(예컨대 라우릴 황산 나트륨), 착색제, 풍미제, 정제화제, 안정화제, 항산화제, 보존제, 물, 식염수, 인산염 완충 용액 등을 들 수 있다. 이러한 담체는 본 발명의 약제학적 조성물의 제형에 따라 적당한 것을 하나 이상 선택하여 사용할 수 있다.Examples of pharmaceutically acceptable carriers include lactose, glucose, sucrose, starch (such as corn starch, potato starch, etc.), cellulose, derivatives thereof (such as sodium carboxymethyl cellulose, ethylcellulose, etc.), malt, gelatin, talc, Solid lubricants (such as stearic acid, magnesium stearate, etc.), calcium sulfate, vegetable oils (such as peanut oil, cottonseed oil, sesame oil, olive oil, etc.), polyols (such as propylene glycol, glycerin, etc.), alginic acid, emulsifiers (such as TWEENS), wetting agents (Such as sodium lauryl sulfate), colorants, flavors, tableting agents, stabilizers, antioxidants, preservatives, water, saline, phosphate buffer solutions, and the like. The carrier may be selected from one or more of suitable pharmaceutical formulations according to the formulation of the pharmaceutical composition of the present invention.
부형제도 본 발명의 약제학적 조성물의 제형에 따라 적합한 것을 선택하여 사용할 수 있는데, 예컨대 본 발명의 약제학적 조성물이 수성 현탁제로 제조될 경우에 적합한 부형제로서는 나트륨 카르복시메틸 셀룰로오스, 메틸 셀룰로오스, 히드로프로필메틸셀룰로오스, 알긴산 나트륨, 폴리비닐피롤리돈 등의 현탁제나 분산제 등을 들 수 있다. 주사액으로 제조되는 경우 적합한 부형제로서는 링거액, 등장 염화나트륨 등을 들 수 있다.Excipients may be selected and used according to the formulation of the pharmaceutical composition of the present invention, for example, when the pharmaceutical composition of the present invention is prepared with an aqueous suspending agent, suitable excipients are sodium carboxymethyl cellulose, methyl cellulose, hydropropylmethylcellulose And suspending agents and dispersing agents such as sodium alginate and polyvinylpyrrolidone. Suitable excipients when prepared from injection solutions include Ringer's solution, isotonic sodium chloride, and the like.
본 발명의 약제학적 조성물은 경구 또는 비경구로 투여될 수 있고, 바람직하게는 국소적으로 투여될 수 있다.The pharmaceutical compositions of the present invention may be administered orally or parenterally, and preferably topically.
본 발명의 약제학적 조성물은 그 1일 투여량이 통상 0.001 ~ 150 mg/kg 체중 범위이고, 1회 또는 수회로 나누어 투여할 수 있다. 그러나, 본 발명의 약제학적 조성물의 투여량은 투여 경로, 환자의 연령, 성별, 체중, 환자의 중증도 등의 여러 관련 인자에 비추어 결정되는 것이므로 상기 투여량은 어떠한 측면으로든 본 발명의 범위를 제한하는 것으로 이해되어서는 아니된다. The daily dose of the pharmaceutical composition of the present invention is usually 0.001 to 150 mg / kg body weight, and may be administered once or several times. However, since the dosage of the pharmaceutical composition of the present invention is determined in view of various related factors such as route of administration, age, sex, weight, and patient's severity of the patient, the dose is limited in any aspect to the scope of the present invention Should not be understood to be.
본 발명의 조성물은 구체적인 양태에 있어서, 기능성 음료 등의 식품 조성물로 파악할 수 있다. The composition of this invention can be grasped | ascertained by food compositions, such as a functional drink, in a specific aspect.
본 발명의 식품 조성물에는 그 유효성분 이외에 감미제, 풍미제, 생리활성 성분, 미네랄 등이 포함될 수 있다.The food composition of the present invention may contain sweetening agents, flavoring agents, physiologically active ingredients, minerals and the like in addition to the active ingredients thereof.
감미제는 식품이 적당한 단맛을 나게 하는 양으로 사용될 수 있으며, 천연의 것이거나 합성된 것일 수 있다. 바람직하게는 천연 감미제를 사용하는 경우인데, 천연 감미제로서는 옥수수 시럽 고형물, 꿀, 수크로오스, 프룩토오스, 락토오스, 말토오스 등의 당 감미제를 들 수 있다. Sweetening agents may be used in an amount that sweetens the food in a suitable manner, and may be natural or synthetic. Preferably, natural sweeteners are used. Examples of natural sweeteners include sugar sweeteners such as corn syrup solids, honey, sucrose, fructose, lactose and maltose.
풍미제는 맛이나 향을 좋게 하기 위하여 사용될 수 있는데, 천연의 것과 합성된 것 모두 사용될 수 있다. 바람직하게는 천연의 것을 사용하는 경우이다. 천연의 것을 사용할 경우에 풍미 이외에 영양 강화의 목적도 병행할 수 있다. 천연 풍미제로서는 사과, 레몬, 감귤, 포도, 딸기, 복숭아 등에서 얻어진 것이거나 녹차잎, 둥굴레, 대잎, 계피, 국화 잎, 자스민 등에서 얻어진 것일 수 있다. 또 인삼(홍삼), 죽순, 알로에 베라, 은행 등에서 얻어진 것을 사용할 수 있다. 천연 풍미제는 액상의 농축액이나 고형상의 추출물일 수 있다. 경우에 따라서 합성 풍미제가 사용될 수 있는데, 합성 풍미제는 에스테르, 알콜, 알데하이드, 테르펜 등이 이용될 수 있다. Flavors may be used to enhance taste or flavor, both natural and synthetic. Preferably, a natural one is used. When using natural ones, the purpose of nutritional fortification can be performed in addition to the flavor. The natural flavor may be obtained from apples, lemons, citrus fruits, grapes, strawberries, peaches, and the like, or may be obtained from green tea leaves, round leaves, jujube leaves, cinnamon, chrysanthemum leaves, jasmine and the like. Also, those obtained from ginseng (red ginseng), bamboo shoots, aloe vera, banks and the like can be used. The natural flavoring agent may be a liquid concentrate or a solid form of extract. Synthetic flavors may be used depending on the case, and synthetic flavors such as esters, alcohols, aldehydes, terpenes and the like may be used.
생리 활성 물질로서는 카테킨, 에피카테킨, 갈로가테킨, 에피갈로카테킨 등의 카테킨류나, 레티놀, 아스코르브산, 토코페롤, 칼시페롤, 티아민, 리보플라빈 등의 비타민류 등이 사용될 수 있다.As the physiologically active substance, catechins such as catechin, epicatechin, gallocatechin, epigallocatechin, vitamins such as retinol, ascorbic acid, tocopherol, calciferol, thiamine, riboflavin, and the like can be used.
미네랄로서는 칼슘, 마그네슘, 크롬, 코발트, 구리, 불소화물, 게르마늄, 요오드, 철, 리튬, 마그네슘, 망간, 몰리브덴, 인, 칼륨, 셀레늄, 규소, 나트륨, 황, 바나듐, 아연 등이 사용될 수 있다.As the mineral, calcium, magnesium, chromium, cobalt, copper, fluoride, germanium, iodine, iron, lithium, magnesium, manganese, molybdenum, phosphorus, potassium, selenium, silicon, sodium, sulfur, vanadium and zinc can be used.
또한 본 발명의 식품 조성물은 상기 감미제 등 이외에도 필요에 따라 보존제, 유화제, 산미료, 점증제 등을 포함할 수 있다. In addition, the food composition of the present invention may contain preservatives, emulsifiers, acidifiers, thickeners and the like as needed in addition to the above sweeteners.
이러한 보존제, 유화제 등은 그것이 첨가되는 용도를 달성할 수 있는 한 극미량으로 첨가되어 사용되는 것이 바람직하다. 극미량이란 수치적으로 표현할 때 식품 조성물 전체 중량을 기준으로 할 때 0.0005중량% 내지 약 0.5중량% 범위를 의미한다.Such preservatives, emulsifiers and the like are preferably added in a very small amount as long as they can attain an application to which they are added. The term " trace amount " means, when expressed numerically, in the range of 0.0005% by weight to about 0.5% by weight based on the total weight of the food composition.
사용될 수 있는 보존제로서는 소듐 소르브산칼슘, 소르브산나트륨, 소르브산칼륨, 벤조산칼슘, 벤조산나트륨, 벤조산칼륨, EDTA(에틸렌디아민테트라아세트산) 등을 들 수 있다. Examples of the preservative which can be used include calcium sodium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate and EDTA (ethylenediaminetetraacetic acid).
사용될 수 있는 유화제로서는 아카시아검, 카르복시메틸셀룰로스, 잔탄검, 펙틴 등을 들 수 있다.Examples of the emulsifier which can be used include acacia gum, carboxymethyl cellulose, xanthan gum, pectin and the like.
사용될 수 있는 산미료로서는 연산, 말산, 푸마르산, 아디프산, 인산, 글루콘산, 타르타르산, 아스코르브산, 아세트산, 인산 등을 들 수 있다. 이러한 산미료는 맛을 증진시키는 목적 이외에 미생물의 증식을 억제할 목적으로 식품 조성물이 적정 산도로 되도록 첨가될 수 있다.Examples of the acidulant that can be used include acid, malic acid, fumaric acid, adipic acid, phosphoric acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, and phosphoric acid. Such an acidulant may be added so that the food composition has a proper acidity for the purpose of inhibiting the growth of microorganisms other than the purpose of enhancing the taste.
사용될 수 있는 점증제로서는 현탁화 구현제, 침강제, 겔형성제, 팽화제 등을 들 수 있다.
Thickeners that can be used include suspending implements, sedimenters, gel formers, swelling agents and the like.
전술한 바와 같이, 본 발명에 따르면 천연물로서 대잎 추출물과 호장근 추출물을 이용한 아토피 피부염 개선제 조성물을 제공할 수 있다. As described above, according to the present invention, it is possible to provide an atopic dermatitis improving agent composition using a natural extract and a rose root extract as a natural product.
본 발명의 조성물에서 아토피 피부염 개선 활성을 나타내는 대잎 추출물과 호장근 추출물은 대잎 추출물 또는 호장근 추출물을 단독으로 사용할 때보다 아토피 피부염 개선 활성이 뛰어나다.In the composition of the present invention, the extract of the leaf and the root of the root of the atopic dermatitis improves the activity of the atopic dermatitis is better than the extract of the leaf or the root of the root.
본 발명의 아토피 피부염 개선제 조성물은 화장품, 비누, 약품, 식품 등으로 제품화될 수 있다.
The atopic dermatitis improving composition of the present invention can be commercialized in cosmetics, soaps, drugs, foods and the like.
이하 본 발명은 참조예, 실시예, 비교예 및 실험예를 참조하여 설명한다. 그러나 본 발명의 범위가 이러한 참조예, 실시예, 비교예 및 실험예에 한정되는 것은 아니다.
Hereinafter, the present invention will be described with reference to reference examples, examples, comparative examples and experimental examples. However, the scope of the present invention is not limited to these reference examples, examples, comparative examples and experimental examples.
<< 참조예Reference Example > > 대잎Leaves 추출물과 Extracts 호장근Ho Jang Geun 추출물의 제조 Preparation of extract
<참조예 1> 대잎 추출물의 제조 <Reference Example 1> Preparation of extract daeip
대잎 세절물을 70% 에탄올에 침지시켜 24시간 동안 교반하면서 추출하였다. 추출액을 2㎛ 여과지로 여과한 후 그 여과액을 감압 농축하여 고형상의 추출물을 얻었다. The leaf slices were immersed in 70% ethanol and extracted with stirring for 24 hours. The extract was filtered through 2 쨉 m filter paper, and the filtrate was concentrated under reduced pressure to obtain a solid extract.
<참조예 2> 호장근 추출물의 제조 REFERENCE EXAMPLE 2 Preparation of Rhododendron Root Extract
호장근 세절물을 70% 에탄올에 침지시켜 24시간 동안 교반하면서 추출하였다. 추출액을 2㎛ 여과지로 여과한 후 그 여과액을 감압 농축하여 고형상의 추출물을 얻었다.
Kho-Geun-Sec was immersed in 70% ethanol and extracted with stirring for 24 hours. The extract was filtered with 2 μm filter paper, and the filtrate was concentrated under reduced pressure to obtain a solid extract.
<< 실시예Example > > 대잎Leaves 추출물 및 Extract and 호장근Ho Jang Geun 추출물을 포함하는 화장수 조성물의 제조 Preparation of the lotion composition comprising the extract
아래의 [표 1]에서와 같이, 상기 참조예의 대잎 추출물과 호장근 추출물 그리고 통상의 화장수 성분들을 혼합하여 임상평가에 사용할 화장수 조성물을 제조하였다. As shown in Table 1 below, the leaf extract of the Reference Example and the extract of Kwon Keun-geun and the usual lotion components were mixed to prepare a lotion composition for use in clinical evaluation.
<< 비교예Comparative example > > 대잎Leaves 추출물 또는 Extract or 호장근Ho Jang Geun 추출물을 이용한 화장수 조성물의 제조 Preparation of Cosmetic Formula Using Extract
아래의 [표 2]에서와 같이, 상기 참조예의 대잎 추출물 또는 호장근 추출물에 통상의 화장수 성분들을 혼합하여 임상평가에 사용할 화장수 조성물을 제조하였다. As shown in Table 2 below, by preparing a lotion composition to be used for clinical evaluation by mixing the common lotion components to the extract of the leaf or the extract of the root of the reference example.
<< 실험예Experimental Example > > 아토피 피부염 개선 활성 실험Atopic dermatitis improvement activity experiment
<실험예 1> 항알러지 활성 실험 Experimental Example 1 Anti-allergic Activity Experiment
RBL-2H3 세포주를 10% FBS(Fetal bovine serum)와 L-글루타민을 포함하고 DMEM(Dulbeccos' modified Eagle's medium) 배지를 이용하여 37℃, 5% CO2 배양기에서 배양하였다. monoclonal antibody IgE(0.5㎍/ml)를 포함하는 DMEM 배지가 들어 있는 24 well plate에 세포를 5 ×105/well로 분주하고 24시간 배양한 후 세포를 well당 시라가니안(siraganian) 완충액 500㎕를 사용하여 헹구어내었다. 다음 160㎕의 시라가니안 완충액(5.6mM 포도당, 1mM CaCl2, 0.1% BSA를 포함)을 넣은 다음에 37℃에서 10분간 배양하였다. 그리고 상기 참조예의 시료(<참조예 1>의 대잎 추출물, <참조예 2>의 호장근 추출물, 및 <참조예 1>의 대잎 추출물과 <참조예 2>의 호장근 추출물의 동량의 혼합물)를 농도별로 처리한 후 20분 동안 배양하고 0.02ml의 항원(DNP-BSA 1㎍/ml)을 처리하고 37℃에서 10분간 세포들을 활성시켰다. 10분간 ice bath에 처리하여 반응을 정지시킨 후 원심분리하였다. 원심분리하여 얻은 0.02 ml의 상등액에 0.02 ml의 기질액 1mM p-NAG(p-nitrophenyl-N-acetyl-β-D-glucosaminide)를 처리한 후, 이를 37℃, 5% CO2 에서 60분간 반응시킨 다음 0.1M Na2CO3/NaHCO3 0.2ml를 가하여 반응을 정지시켰다. 405 nm에서 ELISA reader로 흡광도를 측정하였다.The RBL-2H3 cell line was incubated in a 37 ° C., 5% CO 2 incubator using Dulbeccos' modified Eagle's medium (DMEM) medium containing 10% FBS (Fetal bovine serum) and L-glutamine. Dispense the cells at 5 x 10 5 / well in a 24 well plate containing DMEM medium containing monoclonal antibody IgE (0.5 µg / ml), incubate for 24 hours, and 500 µl of siraganian buffer per well. Rinse using. Next, 160 μl of shigaranean buffer (containing 5.6 mM glucose, 1 mM CaCl 2, 0.1% BSA) was added thereto, and then incubated at 37 ° C. for 10 minutes. And the sample of the reference example (a mixture of the same amount of the bamboo leaf extract of <Reference Example 1>, the Kwon-Geun extract of <Reference Example 2>, and the leaf extract of <Reference Example 1> and the extract of the Kwon-Geun extract of <Reference Example 2> After treatment by concentration, the cells were incubated for 20 minutes, treated with 0.02 ml of antigen (DNP-BSA 1 μg / ml), and the cells were activated at 37 ° C. for 10 minutes. The reaction was stopped by treatment in an ice bath for 10 minutes and then centrifuged. 0.02 ml of the supernatant obtained by centrifugation was treated with 0.02 ml of 1mM p-NAG (p-nitrophenyl-N-acetyl-β-D-glucosaminide), which was then reacted for 60 minutes at 37 ° C. and 5% CO 2 . After the reaction, 0.2 ml of 0.1 M Na 2 CO 3 / NaHCO 3 was added to stop the reaction. Absorbance was measured with an ELISA reader at 405 nm.
결과를 베타-헥소사미니다아제의 유리 억제 효과에 대해 50% 억제하는데 필요한 농도(IC50)로 아래의 [표 3]에 나타내었다.The results are shown in Table 3 below with the concentrations required to inhibit 50% of the free inhibitory effect of beta-hexosaminidase (IC 50 ).
상기 [표 3]의 결과는 대잎 추출물과 호장근 추출물도 비교적 낮은 농도에서 베타-헥소사미니다아제의 유리 억제 활성(IC50)을 보였으나, 대잎 추출물과 호장근 추출물의 혼합물이 경우 매우 낮은 농도에서 베타-헥소사미니다아제의 유리 억제 활성(IC50)을 보였다. The results of Table 3 showed the free inhibitory activity of beta-hexosaminidase (IC 50 ) at relatively low concentrations, but also at very low concentrations. Showed free inhibitory activity (IC 50 ) of beta-hexosaminidase.
특히 대잎 추출물과 호장근 추출물의 혼합물의 경우 60 ㎍/ml 농도에서 92%의 베타-헥소사미니다아제의 유리 억제 활성을 보인 반면, 100 ㎍/ml의 농도에서 대잎 추출물은 78% 억제 활성을 보였고, 호장근 추출물은 82%의 억제 활성을 보였다. In particular, the mixtures of the extracts of the leaves and K. koji extract showed 92% of the inhibitory activity of beta-hexosaminidase at the concentration of 60 ㎍ / ml, whereas the extract of the leaves was 78% of the inhibitory activity at the concentration of 100 ㎍ / ml. , Keun-Geun extract showed 82% inhibitory activity.
<실험예 2> 아토피 피부염의 개선 활성 임상평가 Experimental Example 2 Clinical Evaluation of Improvement Activity of Atopic Dermatitis
상기 실시예의 화장수 조성물과 <비교예 1 및 2>의 화장수 조성물을 이용하여 임상평가를 실시하였다. 임상평가는 아토피 피부염을 앓고 있는 소아 5명을 1 그룹의 실험군으로 하여 아침, 저녁으로 2회씩 총 6주 동안 도포하게 하였다.Clinical evaluation was performed using the lotion composition of the above example and the lotion composition of <Comparative Examples 1 and 2>. The clinical evaluation included five children with atopic dermatitis in a group of six groups for two weeks, morning and evening.
6주 경과 후의 아토피 피부염의 개선 활성은 SCORAD 지수(SCORing Atopic Dermatitis Index, 아토피 증상이 심할수록 높은 수치로 나타남)로 평가하였는데, SCORAD 지수는 The European Task Force on Atopic Dermatitis가 개발한 것으로 가장 널리 사용되고 있는 아토피 피부염의 중증도 지수이다. 통상 SCORAD 지수를 통한 아토피 피부염 중증도 평가에서 SCORAD 지수가 25 이하인 경우 경증으로 분류하고, 26 내지 55인 경우 중등증으로 분류하며, 56 이상인 경우 중증으로 분류하고 있다. The improvement of atopic dermatitis after 6 weeks was evaluated by the SCORAD Index (SCORAD Atopic Dermatitis Index). Severity index of atopic dermatitis. In the evaluation of severity of atopic dermatitis through the SCORAD index, the SCORAD index is classified as mild when 25 or less, as severe as 26 to 55, and as severe when 56 or more.
모든 실험 결과는 Mean±SD 값으로 나타냈으며, ANOVA 분석을 실시하고, Duncan 테스트로 유의차를 검증하였다(p<0.05이고 **는 p<0.01임).All experimental results were expressed as Mean ± SD, ANOVA analysis was performed, and the significant difference was verified by Duncan test ( p <0.05 and ** is p <0.01).
결과는 아래의 [표 4]와 같다. The results are shown in [Table 4] below.
상기 <표 4>의 결과도 대잎 추출물과 호장근 추출물의 동량의 혼합물을 사용하여 제조한 실시예의 화장수 조성물이 상기 각각의 추출물을 사용하여 제조한 화장수 조성물에 비하여 높은 아토피 피부염 개선 활성을 보여, 상기 <실험예 1>의 결과와 유사한 경향을 보였다. The results of Table 4 also show a higher atopic dermatitis improving activity compared to the cosmetic composition of the embodiment prepared by using the same amount of the mixture of the extract of jujube and kojanggeun extract, respectively. The results were similar to those of <Experimental Example 1>.
Claims (7)
상기 대잎 추출물은 대잎을 물, 에탄올 또는 이들의 혼합 용매로 추출하고 얻어진 것이고,
상기 호장근 추출물은 호장근을 물, 에탄올 또는 이들의 혼합 용매로 추출하고 얻어진 것임을 특징으로 하는
아토피 피부염 개선제 조성물.
It includes a leaf extract and keun root extract as an active ingredient,
The said extract of the leaves is obtained by extracting the leaves with water, ethanol or a mixed solvent thereof,
The extract of Keunjangeun is obtained by extracting Kwonjangeun with water, ethanol or a mixed solvent thereof
Atopic dermatitis improver composition.
상기 조성물은 화장품 조성물인 것을 특징으로 하는 아토피 피부염 개선제 조성물.
The method of claim 1,
The composition is atopic dermatitis improving composition, characterized in that the cosmetic composition.
상기 조성물은 비누 조성물인 것을 특징으로 하는 아토피 피부염 개선제 조성물.
The method of claim 1,
The composition is an atopic dermatitis improving composition, characterized in that the soap composition.
상기 조성물은 약품 조성물인 것을 특징으로 하는 아토피 피부염 개선제 조성물.
The method of claim 1,
The composition is atopic dermatitis improving composition, characterized in that the pharmaceutical composition.
상기 조성물은 식품 조성물인 것을 특징으로 하는 아토피 피부염 개선제 조성물.
The method of claim 1,
The composition is atopic dermatitis improving composition, characterized in that the food composition.
상기 조성물은 음료인 것을 특징으로 하는 아토피 피부염 개선제 조성물.
The method according to claim 6,
The composition is atopic dermatitis improver composition, characterized in that the beverage.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100091880A KR101242941B1 (en) | 2010-09-17 | 2010-09-17 | Composition for Atopy Skin Using an Extract of Bamboo Leaves and an Extract of Root of Polygonum |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100091880A KR101242941B1 (en) | 2010-09-17 | 2010-09-17 | Composition for Atopy Skin Using an Extract of Bamboo Leaves and an Extract of Root of Polygonum |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20120029811A KR20120029811A (en) | 2012-03-27 |
KR101242941B1 true KR101242941B1 (en) | 2013-03-12 |
Family
ID=46134140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100091880A KR101242941B1 (en) | 2010-09-17 | 2010-09-17 | Composition for Atopy Skin Using an Extract of Bamboo Leaves and an Extract of Root of Polygonum |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101242941B1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100824970B1 (en) * | 2006-12-26 | 2008-04-28 | 건국대학교 산학협력단 | Polygoni cuspidati radix extract for allergic disease and process for preparation thereof |
KR20100091491A (en) * | 2009-02-10 | 2010-08-19 | 한국식품연구원 | Composition comprising cudrania tricuspidata leaf and wax gourd for inhibiting atopic dermatitis |
-
2010
- 2010-09-17 KR KR1020100091880A patent/KR101242941B1/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100824970B1 (en) * | 2006-12-26 | 2008-04-28 | 건국대학교 산학협력단 | Polygoni cuspidati radix extract for allergic disease and process for preparation thereof |
KR20100091491A (en) * | 2009-02-10 | 2010-08-19 | 한국식품연구원 | Composition comprising cudrania tricuspidata leaf and wax gourd for inhibiting atopic dermatitis |
Also Published As
Publication number | Publication date |
---|---|
KR20120029811A (en) | 2012-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102126470B1 (en) | Cosmetic Composition for comprising longanae arillus extracts | |
KR101883371B1 (en) | The composition of Cordyceps militaris comprising codycepin for inhibting dissolution codycepin, and the functional foods composition | |
EP1312373B1 (en) | Antiallergic agents, drugs, foods, drinks or cosmetics containing them and process for producing the same | |
KR101611853B1 (en) | Aster glehni fractions or compounds isolated therefrom having anti-inflammatory activity | |
KR101367961B1 (en) | Compositoin for Improving Atopic Dermatitis | |
KR101315346B1 (en) | Compositions for Improving Skin Conditions Using an Extract of Stichopus japonicus Red | |
KR101223749B1 (en) | Composition for Improving Atopy Dermatitis Using a Extract of Humulus japonicus or a Extract of Quercus acuta | |
KR101455842B1 (en) | Anti-Inflammation Composition and an Improvment Composition of Atopic Dermatitis Using an Extract of Immature Fruit of Diospyros kaki | |
KR20120029116A (en) | Composition for atopy skin using a fermentive product of leaves of chamaecyparis obtusa | |
KR101501538B1 (en) | Composition for External Application to the Skin Using an Extract of Seeds of Opuntia ficus-indica var. saboten | |
KR101242941B1 (en) | Composition for Atopy Skin Using an Extract of Bamboo Leaves and an Extract of Root of Polygonum | |
KR101999374B1 (en) | Composition for Improving Atopic Dermatitis Using Fermented Products of Fruit of Diospyros kaki | |
KR102106440B1 (en) | Composition for improving skin condition comprising blueberry and black rice extract fermented lactic acid bacteria | |
KR102119307B1 (en) | Composition for Anti-inflammation Using Extract of Salix sp. Plant | |
KR20130009238A (en) | Composition for improving skin diseases | |
KR102014961B1 (en) | Composition for anti oxidation containing extract of soybean pod | |
KR20220060570A (en) | Composition for Improving for Atopic Dermatitis, Pruritis, and Inflammation Comprising Sparasis crispa, vegetable worms, and Tuber melanosporum as Active Ingredient | |
KR101490512B1 (en) | Anti-Inflammation Composition and an Improvment Composition of Atopic Dermatitis Using an Extract of Immature Fruit of Diospyros kaki | |
KR102497941B1 (en) | Compositions for anti-inflammation and anti-allergy using an extract of Artemisia stolonifera | |
KR102247331B1 (en) | Compositions for Improving Skin Wrinkles and Anti-oxidative Composition Using an Extract of Boehmeria tricuspis var. unicuspis | |
KR102247336B1 (en) | Compositions for Improving Skin Wrinkles and Anti-oxidative Composition Using an Extract of Boehmeria tricuspis | |
KR102014960B1 (en) | Composition for anti oxidation containing extract of soybean root | |
KR20170080094A (en) | Composition for improving skin conditions comprising 4-(4-Hydroxyphenyl)-2-butanone | |
KR20150029491A (en) | Composition for improvinig psoriasis | |
KR101906573B1 (en) | Composition for skin cell regeneration or anti-wrinkle comprising garcinia cambogia fruit extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20160307 Year of fee payment: 4 |
|
LAPS | Lapse due to unpaid annual fee |